LXRX
Lexicon Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Lexicon Pharmaceuticals, Inc. (LXRX) closed at $1.56 as of 2026-03-20, trading 6.5% below its 200-week moving average of $1.67. This places LXRX in the deep value zone. The stock is currently moving closer to the line, down from 1.2% last week. The 14-week RSI sits at 56, indicating neutral momentum.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.89 ratio) is neutral — neither side is clearly dominating.
Over the past 1306 weeks of data, LXRX has crossed below its 200-week moving average 17 times. On average, these episodes lasted 64 weeks. The average one-year return after crossing below was -18.0%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $661 million, LXRX is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -39.7%. The stock trades at 5.3x book value.
Share count has increased 92.6% over three years, indicating dilution.
Over the past 25.1 years, a hypothetical investment of $100 in LXRX would have grown to $3, compared to $876 for the S&P 500. LXRX has returned -12.6% annualized vs 9.0% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 5 open-market purchases totaling $2,722,625. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while LXRX is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: LXRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After LXRX Crosses Below the Line?
Across 16 historical episodes, buying LXRX when it crossed below its 200-week moving average produced an average return of -15.6% after 12 months (median -15.0%), compared to +10.8% for the S&P 500 over the same periods. 38% of those episodes were profitable after one year. After 24 months, the average return was -30.8% vs +20.9% for the index.
Each line shows $100 invested at the moment LXRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
LXRX has crossed below its 200-week MA 17 times with an average 1-year return of +-18.0% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2001 | Nov 2004 | 190 | 74.0% | +3.8% | -97.3% |
| Jan 2005 | Jan 2005 | 1 | 0.2% | -40.7% | -96.7% |
| Jan 2005 | Mar 2006 | 60 | 40.3% | -41.0% | -96.7% |
| Apr 2006 | Jan 2011 | 248 | 74.8% | -28.1% | -95.5% |
| Jan 2011 | Jan 2012 | 53 | 44.4% | -27.9% | -88.3% |
| May 2012 | May 2012 | 2 | 1.6% | +32.7% | -85.1% |
| Dec 2013 | Dec 2013 | 2 | 2.9% | -51.7% | -87.3% |
| Feb 2014 | Aug 2015 | 80 | 53.0% | -51.1% | -87.8% |
| Sep 2015 | Nov 2015 | 6 | 22.6% | +66.6% | -86.0% |
| Dec 2015 | Dec 2015 | 1 | 0.7% | +27.0% | -87.3% |
| Jan 2016 | Mar 2016 | 12 | 29.2% | +30.0% | -86.1% |
| May 2016 | May 2016 | 2 | 0.5% | +31.0% | -87.2% |
| Oct 2017 | May 2018 | 34 | 33.6% | -19.3% | -86.7% |
| Jul 2018 | Jan 2021 | 129 | 89.6% | -89.0% | -85.7% |
| Mar 2021 | Oct 2021 | 31 | 42.3% | -68.6% | -77.0% |
| Oct 2021 | Mar 2026 | 228 | 84.7% | -62.0% | -69.4% |
| Mar 2026 | Ongoing | 1+ | 6.5% | Ongoing | N/A |
| Average | 64 | — | +-18.0% | — |
Frequently Asked Questions
Is LXRX below its 200-week moving average?
Yes. As of 2026-03-20, Lexicon Pharmaceuticals, Inc. (LXRX) is trading 6.5% below its 200-week moving average of $1.67. The current price is $1.56.
What is LXRX's 200-week moving average price?
Lexicon Pharmaceuticals, Inc.'s 200-week moving average is $1.67 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when LXRX drops below its 200-week moving average?
LXRX has crossed below its 200-week moving average 17 times in our data. The average one-year return after these crossings was -18.0%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 64 weeks on average.
Is LXRX a good value right now?
Here's what our data says about LXRX as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 56. Free cash flow is currently negative. Return on equity is -39.7%. Price-to-book is 5.3x. This is not a buy or sell recommendation — always do your own research.
How does LXRX compare to the S&P 500?
Over the past 25.1 years, $100 invested in LXRX would have grown to $3, compared to $876 for the S&P 500. That's -12.6% annualized vs 9.0% for the index. LXRX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20